List of Excipients in Branded Drug LEQSELVI

LEQSELVI Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Leqselvi is the U.S. brand name for deuruxolitinib, an oral deuterated Janus kinase inhibitor approved by the FDA in July 2024 for adults with severe alopecia areata.[1] Its commercial formulation is an immediate-release, film-coated 8 mg tablet taken twice daily. The public label lists conventional oral solid-dose excipients, creating opportunities in generic development, supply-chain optimization, differentiated formulations, and lifecycle management.

The highest-value excipient strategy is likely to preserve rapid dissolution and bioequivalence while improving tablet manufacturability, dose flexibility, patient acceptability, and supply security. Because Leqselvi is a small-molecule drug, biosimilar risk is not relevant. Generic entry through an abbreviated new drug application, including potential Paragraph IV challenges, is the principal long-term competitive threat.

What excipients are used in Leqselvi tablets?

Leqselvi 8 mg tablets use a conventional immediate-release formulation. The FDA prescribing information identifies the following inactive ingredients.[1]

Formulation component	Publicly identified material	Likely function
Diluent	Lactose monohydrate	Adds tablet bulk and supports compression
Filler and compression aid	Microcrystalline cellulose	Improves compactability and tablet strength
Disintegrant	Croscarmellose sodium	Promotes tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Film-coating polymer	Polyvinyl alcohol	Forms the protective film
Opacifier and colorant	Titanium dioxide	Provides opacity and appearance control
Anti-tacking agent	Talc	Improves coating performance
Plasticizer	Polyethylene glycol	Improves film flexibility

The formulation does not rely on an unusual delivery system, lipid carrier, enteric coating, or modified-release technology. That reduces manufacturing complexity and lowers the technical barrier for an ANDA developer, although formulation development still requires control of dissolution, impurities, tablet hardness, coating weight, and stability.

How does the Leqselvi excipient system affect commercial formulation strategy?

The current excipient system is commercially practical but not fully optimized for every patient or manufacturing environment.

Lactose-free opportunity

Lactose is the most visible formulation vulnerability. A lactose-free version could target patients with lactose intolerance, reduce dependence on dairy-derived excipient supply, and support certain international market requirements.

Potential replacements include:

• Mannitol for a low-hygroscopicity, patient-friendly filler
• Dibasic calcium phosphate for high-density direct compression
• Anhydrous lactose for a related but lower-moisture alternative
• Spray-dried mannitol or co-processed cellulose for improved flow and compaction

A lactose-free formulation would not automatically create meaningful differentiation in the U.S. prescription market. It could, however, support product-line segmentation, global registration, hospital formulary requirements, and a future authorized-generic or secondary-brand strategy.

Direct-compression optimization

Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate form a standard direct-compression platform. A manufacturer could evaluate co-processed excipients that combine filler, binder, and disintegration functions.

The commercial advantages include:

• Fewer raw materials
• Shorter blending and compression cycles
• Lower sensitivity to raw-material variability
• Reduced tablet weight
• Improved manufacturing throughput

The tradeoff is regulatory comparability. A substantial excipient change may alter dissolution or tablet microstructure and could require a more extensive bioequivalence package than a conventional composition change.

Magnesium stearate control

Magnesium stearate is effective but can produce hydrophobic over-lubrication when blending time is excessive. That can slow dissolution and increase batch-to-batch variation. Development teams should control:

• Lubrication time
• Shear exposure
• Particle-size distribution
• Specific surface area
• Blend uniformity
• Dissolution after accelerated storage

Alternatives such as sodium stearyl fumarate may improve dissolution robustness in some formulations, but the benefit must be demonstrated against the reference product.

Film-coating and swallowability

Leqselvi tablets are film-coated. Coating suppliers may pursue lower-weight, faster-drying, or pigment-reduced systems. A smoother and thinner film could improve swallowability while reducing coating time and solvent or water demand.

A commercial opportunity exists for:

• Low-tack aqueous coatings
• Titanium-dioxide-reduced coatings
• Color systems that support product authentication
• Higher-opacity coatings for photoprotection
• Smaller tablet dimensions through higher tablet density

Any change affecting appearance, mechanical strength, dissolution, or stability would require comparative pharmaceutical and regulatory assessment.

What formulation patents may protect Leqselvi?

The primary protection for deuruxolitinib is expected to center on the active ingredient, deuterated chemical structure, therapeutic use, and potentially specific solid forms or manufacturing processes. Public FDA labeling does not provide a complete patent map.

Formulation-related protection could cover:

• Specific tablet compositions
• Defined excipient ranges
• Particle-size distributions
• Immediate-release dissolution profiles
• Solid-state forms or polymorphs
• Deuterated active-ingredient manufacturing processes
• Treatment of alopecia areata with defined dosing regimens
• Pharmaceutical compositions with specified impurity limits

A formulation patent is commercially meaningful only if it claims a composition that an ANDA applicant would need to practice. Broad claims covering routine excipient substitutions may face validity and non-infringement challenges. Narrow claims directed to a specific dissolution profile, solid form, or manufacturing condition may create more practical launch friction but can be easier to design around.

What is the FDA regulatory status of Leqselvi?

The FDA approved Leqselvi in July 2024 for adults with severe alopecia areata.[1] The product is an oral 8 mg tablet administered twice daily. The FDA approval followed clinical development by Concert Pharmaceuticals and commercialization by Sun Pharmaceutical Industries through its U.S. specialty pharmaceutical platform.[2]

Leqselvi competes in a class with other oral JAK inhibitors approved or marketed for alopecia areata, including baricitinib and ritlecitinib. The product carries class-related safety considerations involving serious infections, malignancy, major cardiovascular events, thrombosis, and mortality warnings applicable to JAK inhibitor therapy.[1]

The safety profile affects excipient and formulation strategy because unnecessary changes to exposure, dissolution, or absorption could complicate regulatory review. A differentiated formulation should preserve the approved exposure profile unless the sponsor is intentionally pursuing a new clinical or regulatory claim.

When does Leqselvi lose exclusivity?

Leqselvi has several potential exclusivity layers:

1. FDA regulatory exclusivity associated with the approval and any qualifying clinical development.
2. Orange Book-listed patents covering deuruxolitinib, its uses, dosage forms, or manufacturing.
3. Patent term adjustments, patent term extension, pediatric exclusivity, and other statutory extensions.
4. International national patent rights that expire on different dates.

A reliable generic-entry date cannot be derived from the approval date alone. The relevant date is the earliest legally available entry date after accounting for listed patents, regulatory exclusivity, patent-term adjustments, litigation outcomes, and any settlement agreement.

The FDA Orange Book is the controlling public source for listed patents and exclusivity status. A commercial diligence review should reconcile the Orange Book with USPTO prosecution records and federal court dockets rather than relying on a single expiration date.[3]

Are there Paragraph IV challenges to Leqselvi?

A Paragraph IV certification allows an ANDA applicant to assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The first substantially complete ANDA applicant may be eligible for 180-day generic exclusivity if statutory requirements are met.[4]

Public sources cited here do not establish a confirmed, commercially active Paragraph IV challenger to Leqselvi. That does not eliminate future challenge risk. Oral small-molecule products with conventional tablets are structurally vulnerable to generic development because:

• The dosage form is simple.
• The active ingredient is not a biologic.
• The formulation uses common excipients.
• Bioequivalence can generally be evaluated without demonstrating clinical efficacy.
• An ANDA applicant may substitute excipients if the final product meets applicable requirements.

The most likely initial challenge targets would be composition-of-matter, method-of-use, and formulation patents. Manufacturing patents may be less effective if the generic can use a non-infringing synthetic route.

How strong is the Leqselvi patent estate?

The estate is likely strongest where protection is tied to the deuruxolitinib molecule or a technically necessary active-ingredient manufacturing step. It is weaker where protection depends on routine tablet excipients that can be replaced without changing the product’s clinical performance.

Protection category	Strategic strength	Generic design-around risk
Deuruxolitinib composition of matter	High if valid and unexpired	Low
Deuterated synthesis or intermediate	Medium to high	Medium
Approved alopecia areata method of use	Medium	Medium to high
Specific tablet formulation	Medium	Medium to high
Routine excipient combination	Low to medium	High
Film coating composition	Low to medium	High
Manufacturing process with narrow parameters	Medium	Medium

Patent strength also depends on written-description support, enablement, obviousness, claim construction, prosecution history, and whether a generic can avoid the claimed steps.

What commercial opportunities exist for Leqselvi excipients?

Excipient supplier opportunities

Excipient suppliers can target Sun Pharma, contract manufacturers, and future generic entrants with:

• Low-moisture lactose
• Direct-compression mannitol
• Co-processed cellulose systems
• High-functionality croscarmellose sodium
• Low-peroxide excipients
• Alternative lubricants
• High-performance aqueous film coatings
• Excipient lots with tighter particle-size and microbial specifications

Supply qualification is commercially important because a specialty product may depend on a small number of qualified sources. Dual sourcing can reduce interruption risk but may require comparability work.

Generic formulation opportunities

The most practical generic strategy is a close qualitative and quantitative composition using the listed excipients. A second-tier strategy would use a lactose-free or lower-tablet-weight formulation. The latter may create manufacturing or patient-use advantages but carries greater formulation-development risk.

A generic developer should prioritize:

1. Reference-product characterization.
2. Excipient compatibility and forced-degradation studies.
3. Comparative dissolution across pH conditions.
4. Tablet hardness and friability matching.
5. Stability under accelerated and long-term conditions.
6. Bioequivalence risk assessment.
7. Orange Book patent review and Paragraph IV timing.

Lifecycle-management opportunities

A sponsor could pursue:

• A smaller tablet
• A lactose-free tablet
• A tablet with improved swallowability
• Packaging designed for moisture protection
• Geographic variants using locally available excipients
• An authorized generic
• A fixed-dose combination only if clinically justified
• Pediatric or adolescent development if supported by regulatory strategy

A modified-release product is a higher-risk opportunity. It would likely require new pharmacokinetic and clinical evidence and could alter the safety and efficacy profile. It is less attractive than a compositionally optimized immediate-release tablet unless adherence or tolerability data support the investment.

How does Leqselvi compare with competing alopecia areata drugs?

Product	Active ingredient	Dosage form	Competitive excipient implication
Leqselvi	Deuruxolitinib	Immediate-release tablet	Conventional solid-dose optimization is available
Olumiant	Baricitinib	Tablet	Established JAK-class comparator
Litfulo	Ritlecitinib	Capsule	Capsule-based formulation creates different excipient and manufacturing economics
Topical or investigational therapies	Various	Topical or other	Compete through route of administration rather than tablet excipients

Leqselvi’s commercial position depends more on efficacy, safety labeling, payer access, physician adoption, and treatment persistence than on excipient differentiation alone. Excipient changes are most valuable when they reduce cost, improve supply resilience, or support a specific patient or market segment.

What generic launch scenarios exist for Leqselvi?

Three scenarios are commercially plausible:

Early Paragraph IV launch

A challenger attacks key patents before nominal patent expiry and obtains a favorable litigation outcome or settlement allowing an early launch. This scenario creates the greatest revenue shock and can compress pricing rapidly.

At-risk launch

A generic launches before final resolution of patent litigation. This can accelerate market disruption but exposes the challenger to damages and injunctive risk.

Post-expiry launch

Generic entry follows patent expiration or a settlement date. Price erosion would depend on the number of approved ANDAs, payer substitution, authorized-generic participation, and whether the product has meaningful clinical differentiation.

For a specialty oral drug, the first generic may not produce the same immediate substitution rate as a primary-care product. Specialty pharmacy distribution, payer controls, and prescriber behavior can delay or moderate conversion.

What geographic opportunities exist?

The U.S. is the principal reference market because FDA approval and Orange Book listing determine the initial generic framework. Ex-U.S. opportunities require separate analysis of:

• National patent term
• Supplementary protection certificates
• Data exclusivity
• Local excipient restrictions
• Reliance or abridged regulatory pathways
• Import and manufacturing rules
• Pricing and reimbursement controls

A lactose-free formulation may have greater commercial value in markets where lactose intolerance is prevalent or where local procurement favors specific excipient profiles. The same formulation can also simplify regional product segmentation if the sponsor uses a common global platform.

Key Takeaways

• Leqselvi is an 8 mg immediate-release tablet containing conventional excipients, including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and a standard film coat.[1]
• The strongest excipient opportunities are lactose replacement, direct-compression optimization, film-coating efficiency, and supply-chain dual sourcing.
• Excipient differentiation alone is unlikely to produce durable market exclusivity unless supported by enforceable formulation or process claims.
• Leqselvi faces generic rather than biosimilar risk.
• Paragraph IV litigation is the main potential route to accelerated generic entry.
• The molecule and active-ingredient manufacturing claims are likely to have greater defensive value than routine tablet-composition claims.
• Commercial performance will depend primarily on clinical positioning, payer access, safety management, and treatment persistence.
• The FDA Orange Book and USPTO records should control any final exclusivity or launch-date assessment.[3]

FAQs About Leqselvi Excipient and Commercial Strategy

Can Leqselvi be reformulated without lactose?

Yes. Mannitol, dibasic calcium phosphate, anhydrous lactose, or co-processed excipients could replace lactose, but the reformulated product would require comparative pharmaceutical testing and may require additional regulatory support.

Is Leqselvi eligible for a biosimilar?

No. Deuruxolitinib is a chemically synthesized small molecule. Competitive products would generally use the ANDA generic pathway rather than the biosimilar pathway.

Would an excipient change create a new patent barrier?

Only if the change is covered by valid, enforceable patent claims. A routine substitution of lactose, binder, disintegrant, or lubricant is generally easier to design around than a claim directed to a novel solid form, process, or clinically meaningful delivery system.

What is the most attractive generic formulation strategy?

A close-copy immediate-release tablet is the lowest-risk path. A lactose-free or smaller tablet is a higher-value but higher-development-risk option because it requires stronger evidence that dissolution and systemic exposure remain comparable.

Which excipient issue is most likely to affect commercial supply?

The principal risks are dependence on qualified excipient suppliers, variability in lactose and cellulose functionality, magnesium-stearate over-lubrication, and coating-material availability. Dual sourcing and tighter incoming specifications can reduce these risks.

References

1. U.S. Food and Drug Administration. (2024). Leqselvi (deuruxolitinib) prescribing information.
2. Sun Pharmaceutical Industries Ltd. (2024). Sun Pharma announces U.S. FDA approval of Leqselvi for severe alopecia areata.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity: Questions and answers.